Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: Analysis of the Radiation Therapy Oncology Group (RTOG) database

Clinical Lung Cancer

Volumn 12, Issue 4, 2011, Pages 245-251

  Werner Wasik, Maria ^a   Paulus, Rebecca ^b   Curran, Walter ^c   Byhardt, Roger ^d  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chemotherapy; Normal tissue; Pneumonitis; Side effects; Swallowing

Indexed keywords

CISPLATIN; ETOPOSIDE; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMORADIOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; RACE DIFFERENCE; RADIATION DOSE FRACTIONATION; RADIATION INJURY;

EID: 79960350182     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.026     Document Type: Article

References (38)

1. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42:469-478. (Pubitemid 28501093)
2. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998; 16:3316-22. (Pubitemid 28481627)
3. Werner-Wasik M, Scott C, Graham ML, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 1999; 44:327-31. (Pubitemid 29205030)
4. Bailey AJ, Parmar MKB, Stephens RJ. Patient-reported short-term and long-term physical and psychologic symptoms: results of the Continuous Hyperfractionated Accelerated Radiotherapy (CHART) randomized trial innon-small cell lung cancer. J Clin Oncol 1998; 16:3082-93. (Pubitemid 28417430)
5. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:318-28. (Pubitemid 40164423)
6. Byhardt RW, Scott CB, Ettinger DS, et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer 1995; 75:2337-44.
7. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 1996; 14:1055-64. (Pubitemid 26105509)
8. Komaki R, Seiferheld W, Ettinger D, et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002; 53:548-57. (Pubitemid 34626492)
9. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of RTOG 9410. Proc ASCO 2000; 19:484a
10. RTOG Radiation Therapy Oncology Group. Acute Radiation Morbidity Scoring Criteria. Available at: http://en.wikibooks.org/wiki/Radiation-Oncology/ Toxicity-Grading/RTOG.
11. RTOG Radiation Therapy Oncology Group. RTOG/EORTC Late Radiation Morbidity Scoring Schema. Available at: http://en.wikibooks.org/wiki/Radiation- Oncology/Toxicity-Grading/RTOG.
12. Prentice RL, Kalbfleisch JD. Hazard rate models with covariates. Biometrics 1979; 35:25-39. (Pubitemid 9136564)
13. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 RTOG trials. Int J Radiat Oncol Biol Phys 1993; 27:493-8. (Pubitemid 23331113)
14. Jeremic B, Shibamoto Y, Milicic B, et al. Concurrent radiochemotherapy for patients with Stage III non-small cell lung cancer: Long term results of a Phase II study. Int J Radiat Oncol Biol Phys 1998; 42:1091-6. (Pubitemid 29004153)
15. Choy H, Devore RF, Hande KR, et al. A Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced non-small cell lung cancer (A Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000; 47:931-7. (Pubitemid 30345590)
16. Lee JS, Komaki R, Fossella FV, et al. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small cell lung cancer: A 5-year follow-up report. Int J Radiat Oncol Biol Phys 1998; 42:479-86. (Pubitemid 28501094)
17. Penney DP, Siemann DW, Rubin P, et al. Morphological correlates of fractionated radiation of the mouse lung: early and late effects. Int J Radiat Oncol Biol 1994; 29:789-804. (Pubitemid 24241320)
18. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
19. Maguire P, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 1999; 45:97-103. (Pubitemid 29380080)
20. Werner-Wasik M, Pequignot E, Leeper D, et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with non-operative therapy. Int J Radiat Oncol Biol Phys 2000; 48:689-696.
21. Belderbos JSA, Heemsbergen WD, Pengel K, et al. Acute esophageal toxicity in non-small cell lung cancer patients after high-dose conformal radiotherapy. Ra-diother and Oncol 2005; 75:157-64. (Pubitemid 40805244)
22. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:337-41. (Pubitemid 36069091)
23. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:995-1002.
24. Ahn SJ, Kahn D, Zhou S, et al. Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 2005; 61:335-47. (Pubitemid 40164425)
25. Bradley J, Deasy JO, Bentzen S, et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004; 58:1106-13. (Pubitemid 38314792)
26. Wei X, Liu HH, Tucker SL, et al. Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:100-7. (Pubitemid 44175670)
27. Graham MV, Purdy JA, Emami B,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 45:323-9. (Pubitemid 29408545)
28. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:1399-407.
29. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose; An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998; 42:1-9. (Pubitemid 28435589)
30. Seppenwoolde Y, Lebesque JV, de Jaeger, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003; 55:724-35. (Pubitemid 36170012)
31. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 2004; 71:127-38. (Pubitemid 38521180)
32. Geara FB, Komaki R, Tucker SL, et al. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: Evidence for inherent interindividual variation. Int J Radiat Oncol Biol Phys 1998; 41:279-86. (Pubitemid 28243538)
33. Helle PA. Pulmonary effects of radiotherapy in patients with inoperable bronchial carcinoma [PhD Thesis]. Daniel den Hoed Cancer Center, Rotterdam Academic Hospital, the Netherlands, 1995.
34. Roach M 3rd, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995; 13:2606-12.
35. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001; 50:899-908. (Pubitemid 32594832)
36. Arpin D, Perol D, Blay JY, et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneu-monitis. J Clin Oncol 2005; 23:8748-56. (Pubitemid 46211520)
37. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010; 77:367-72.
38. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006; 8:116-21. (Pubitemid 44596753)